These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15037537)

  • 1. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity.
    Cipollone F; Fazia M; Iezzi A; Pini B; Cuccurullo C; Zucchelli M; de Cesare D; Ucchino S; Spigonardo F; De Luca M; Muraro R; Bei R; Bucci M; Cuccurullo F; Mezzetti A
    Circulation; 2004 Mar; 109(12):1482-8. PubMed ID: 15037537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New insights on the molecular mechanisms of type-1 angiotensin II receptor blockers and their contribution to atherosclerotic plaque stabilization].
    Mezzetti A; Fazia M; Cipollone F
    Recenti Prog Med; 2004 Dec; 95(12):586-90. PubMed ID: 15666492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
    Cipollone F; Fazia M; Iezzi A; Zucchelli M; Pini B; De Cesare D; Ucchino S; Spigonardo F; Bajocchi G; Bei R; Muraro R; Artese L; Piattelli A; Chiarelli F; Cuccurullo F; Mezzetti A
    Circulation; 2003 Mar; 107(11):1479-85. PubMed ID: 12654603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.
    Cipollone F; Iezzi A; Fazia M; Zucchelli M; Pini B; Cuccurullo C; De Cesare D; De Blasis G; Muraro R; Bei R; Chiarelli F; Schmidt AM; Cuccurullo F; Mezzetti A
    Circulation; 2003 Sep; 108(9):1070-7. PubMed ID: 12912808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability.
    Cipollone F; Prontera C; Pini B; Marini M; Fazia M; De Cesare D; Iezzi A; Ucchino S; Boccoli G; Saba V; Chiarelli F; Cuccurullo F; Mezzetti A
    Circulation; 2001 Aug; 104(8):921-7. PubMed ID: 11514380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans.
    Cipollone F; Fazia M; Iezzi A; Ciabattoni G; Pini B; Cuccurullo C; Ucchino S; Spigonardo F; De Luca M; Prontera C; Chiarelli F; Cuccurullo F; Mezzetti A
    Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1259-65. PubMed ID: 15155382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes.
    Cuccurullo C; Iezzi A; Fazia ML; De Cesare D; Di Francesco A; Muraro R; Bei R; Ucchino S; Spigonardo F; Chiarelli F; Schmidt AM; Cuccurullo F; Mezzetti A; Cipollone F
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2716-23. PubMed ID: 17038636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human.
    Cipollone F; Fazia ML; Iezzi A; Cuccurullo C; De Cesare D; Ucchino S; Spigonardo F; Marchetti A; Buttitta F; Paloscia L; Mascellanti M; Cuccurullo F; Mezzetti A
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1925-31. PubMed ID: 16020747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of angiotensin II receptor blockers in atherosclerotic plaque stability.
    Cipollone F; Fazia ML; Mezzetti A
    Expert Opin Pharmacother; 2006 Feb; 7(3):277-85. PubMed ID: 16448322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.
    Gómez-Hernández A; Martín-Ventura JL; Sánchez-Galán E; Vidal C; Ortego M; Blanco-Colio LM; Ortega L; Tuñón J; Egido J
    Atherosclerosis; 2006 Jul; 187(1):139-49. PubMed ID: 16212965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological modulation of plaque instability.
    Mezzetti A
    Lupus; 2005; 14(9):769-72. PubMed ID: 16218485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression in human carotid atheroma.
    Clancy P; Seto SW; Koblar SA; Golledge J
    Atherosclerosis; 2013 Aug; 229(2):331-7. PubMed ID: 23880184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
    Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
    Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of instability in high-risk carotid plaques are reduced by statins.
    Kunte H; Amberger N; Busch MA; Rückert RI; Meiners S; Harms L
    J Vasc Surg; 2008 Mar; 47(3):513-22. PubMed ID: 18295103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [COX-2 and mPGES-1 expression in carotid atherosclerotic plaques].
    Liu HF; Li XH; Yang QD; Miao W; Qi SS; Song XM; He GS; Dong HL; Zhang FQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):453-6. PubMed ID: 17680542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization.
    Gómez-Hernández A; Sánchez-Galán E; Martín-Ventura JL; Vidal C; Blanco-Colio LM; Ortego M; Vega M; Serrano J; Ortega L; Hernández G; Tunón J; Egido J
    J Cardiovasc Pharmacol; 2006 Jan; 47(1):60-9. PubMed ID: 16424787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.
    Schieffer B; Bünte C; Witte J; Hoeper K; Böger RH; Schwedhelm E; Drexler H
    J Am Coll Cardiol; 2004 Jul; 44(2):362-8. PubMed ID: 15261932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of rupture of atherosclerotic plaque by Candesartan in rabbit model].
    Zhou XF; Yin HC; Zhu WL; Shen L; Yu T; Li SA; Meng ZM; Wu AS; Qian HD
    Zhonghua Bing Li Xue Za Zhi; 2010 Feb; 39(2):106-11. PubMed ID: 20388376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-associated differences in plaque phenotype of patients undergoing carotid endarterectomy.
    Hellings WE; Pasterkamp G; Verhoeven BA; De Kleijn DP; De Vries JP; Seldenrijk KA; van den Broek T; Moll FL
    J Vasc Surg; 2007 Feb; 45(2):289-96; discussion 296-7. PubMed ID: 17264005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.